Objectives: To assess the difference in cost percentage variation of various brands of oral hypoglycaemic drugs available in single and in combination in Indian market.
Materials and Methods: An observational study was carried out using â€˜Current index in medical specialitiesâ€™, â€˜reference Rxâ€™, & â€˜Indian drug referralâ€™ (July-Oct 2014), where in the difference in the maximum and minimum price of a particular drug, manufactured by different pharmaceutical companies, in the same strength, number and dosage form was compared and the percentage variation in price was calculated. Data is analysed using descriptive statistical analysis.
Results: The minimum and maximum percentage price variation for different classes of drugs respectively is as follows: In Single drug therapy, among sulfonylurea group of drugs, Glimepiride (2mg) & Glicazide (80mg) shows maximum and minimum price variation of 730.93% & 165.55% respectively. Among Biguanides & Thiazolidinediones groups, Metformin (500 mg) & Pioglitazone (15mg) show maximum price variation of 402.92% & 483.33% respectively. In Î±-glucosidases inhibitor group of drugs, Voglibose (0.2mg) shows maximum price variation of 451.28 %. Among newer DPP4 (Dipeptide peptidase 4) inhibitors Vildagliptin (50mg) shows maximum cost variation of 100%. In combination therapies Glimipiride & Pioglitazone combination shows the maximum variation up to 307.7%.
Conclusion: The percentage cost variation of different brands of the same drug manufactured in India is very wide and the reason behind marketing a drug should be directed towards maximizing the benefit of therapy and minimizing negative personal and economic consequences.
Cost analysis, Oral hypoglycaemic drugs, Cost evaluation, Price variation